Kalaris Therapeutics appointed Matthew Gall, MBA, as chief financial officer. Mr. Gall most recently served as chief financial officer of iTeos Therapeutics, where he was responsible for business development and overall financial operations and strategy, according to a press release. Prior to his time at iTeos, Gall held positions at Sarepta Therapeutics, Celgene Corporation, and Gilead Sciences across the finance and business development areas. 

“I am delighted to welcome Matthew to our team,” says Andrew Oxtoby, president and chief executive officer of Kalaris Therapeutics, in a press release. “Matt is an experienced chief financial officer and strategic leader with a track record of successfully scaling up biopharmaceutical companies, directing capital raising rounds, and negotiating highly beneficial partnership deals. He will be a valuable addition to our leadership team and will support our company’s evolution, as we advance our clinical development efforts.”

Commenting on his new role at the company, Mr. Gall adds: “I am excited to join Kalaris Therapeutics’ leadership team at this critical time in the company’s trajectory. I look forward to helping Kalaris achieve its mission to change the treatment landscape for those living with retinal diseases.” OM